1 Statins inhibit synthesis of mevalonate, a precursor of ubiquinone that is a central compound of the mitochondrial respiratory chain. The main adverse effect of statins is a toxic myopathy possibly related to mitochondrial dysfunction. 2 This study was designed to evaluate the effect of lipid-lowering drugs on ubiquinone (coenzyme Q10 ) serum level and on mitochondrial function assessed by blood lactate/pyruvate ratio. 3 Eighty hypercholesterolaemic patients (40 treated by statins, 20 treated by fibrates, and 20 untreated patients, all 80 having total cholesterol levels >6.0 mmol l−1) and 20 healthy controls were included. Ubiquinone serum level and blood lactate/pyruvate ratio used as a test for mitochondrial dysfunction were evaluated in all subjects. 4 Lactate/pyruvate ratios were significantly higher in patients treated by statins than in untreated hypercholesterolaemic patients or in healthy controls (P<0.05 and P<0.001). The difference was not significant between fibratetreated patients and untreated patients. 5 Ubiquinone serum levels were lower in statin-treated patients (0.75 mg l−1±0.04) than in untreated hypercholesterolaemic patients ( 0.95 mg l−1±0.09; P<0.05). 6 We conclude that statin therapy can be associated with high blood lactate/ pyruvate ratio suggestive of mitochondrial dysfunction. It is uncertain to what extent low serum levels of ubiquinone could explain the mitochondrial dysfunction.
Introduction
inflammatory myopathies [2] [3] [4] [5] . The pathogenesis of statin-induced muscle involvement is still unclear [ 6, 7] . Patients treated by the combination of statin and Hydroxy-methylglutaryl (HMG)-CoA reductase inhibitors induce unselective inhibition of the common fibrate therapy have been considered at particular risk for myopathy and rhabdomyolysis [8] . Single case mevalonate pathway in liver and are one therapeutic class for the treatment of hypercholesterolaemia [1 ] .
studies have suggested the hypothesis of a mitochondrial dysfunction at the origin of statin- [ 9, 10 ] and fibrateThe therapeutic class includes lovastatin, simvastatin, pravastatin, and fluvastatin (statins). The main clinical related myopathies [ 11] . Statins inhibit synthesis of mevalonate, a precursor of adverse effects of statins are muscular and include elevation of serum creatine kinase, sometimes associated both cholesterol and ubiquinone. Some studies have documented a decrease of serum levels of ubiquinone in with myalgia, rhabdomyolysis, and rarely, cases of patients receiving statins [12] [13] [14] [15] , and it is debated Study design whether or not the decrease of ubiquinone level parallels that of cholesterol level [13, 15] . Ubiquinone (Coenzyme All patients participating in the study had a clinical and neurological examination, including assessment of mus-Q10) is a key-coenzyme of the mitochondrial respiratory chain [16 ] , and a drug-induced decrease of ubiquinone cular strength. Blood lactate and pyruvate and serum levels of total and HDL cholesterol, triglycerides, production might therefore induce mitochondrial dysfunction [13 ] .
ubiquinone, aspartate and alanine aminotransferase, and creatine kinase were assayed on the first day of the Lactic acid is produced by reduction of pyruvate, a product of anaerobic metabolism of glucose, and oxidative study. A second blood sample for lactate and pyruvate was obtained after 1 week. metabolism of pyruvate proceeds partly through the mitochondrial respiratory chain. Dysfunction of the The study was approved by the Ethics Committee of Henri Mondor Hospital and each patient gave respiratory chain may lead to inadequate removal of lactate and pyruvate from the circulation and elevated informed consent. lactate/pyruvate ratios are observed in mitochondrial cytopathies [17, 18] . Patients with two normal evaluations were considered to have normal total cholesterol above 6.0 mmol l−1. Patients in whom lipid-lowering therapy had been modified in the previous lactate/pyruvate ratio. 2 months and patients with high serum creatine kinase levels (>200 iu l−1) or muscular symptoms were not included. Exclusion criteria were as follows: hepatic Ubiquinone determinations failure or elevated serum aminotransferase levels (≥twofold), fever, recent surgery (<2 weeks), recent Ubiquinone levels were determined in serum by high performance liquid chromatography (h.p.l.c.) adapted traumatism or intense physical activity (<2 weeks), treatment by biguanides, or recurrent cerebral ischaemic from Okamoto et al. [ 22, 23] . The analytical conditions for the determination of ubiquinone were as follows: episodes. Group 1 included 40 consecutive hypercholesterolaemic subjects treated by statins: 23 men and 17 stationary phase, C18-5 (5 mm particles) column, stainless-steel, 250×4.6 mm; mobile phase: methanol-n women, aged 21-76 years, median: 51, treated by simvastatin (28 patients), pravastatin (eight patients), or hexane (75525); flow rate: 1 ml min−1; range: 0.08; measuring wavelength: 275 nm. The h.p.l.c. measurefluvastatin (four patients). Group 2 included 20 consecutive hypercholesterolaemic subjects treated by fibrates:
ments were performed at room temperature. Extraction was performed as follows: 0.4 ml plasma from hep-16 men and four women, aged 38-70 years, median: 54, treated by ciprofibrate (nine patients), fenofibrate (eight arinized venous blood were pipetted into a stoppered brown-glass tube and 0.3 ml distilled water and 7 ml of patients), or gemfibrozil (three patients). Group 3 included 20 consecutive hypercholesterolaemic subjects a mixture of ethanol/n-hexane (255) were added. The tube was then rapidly shaken for 10 min and centrifuged who did not receive any cholesterol-lowering drug: 12 men and eight women, aged 27-75 years, median: 46. A at 500 g for 10 min. This extraction procedure was repeated three times. The combined n-hexane phase was group of 20 subjects (11 men and nine women, aged 25-66 years, median: 35 ) without hypercholesterolaemia evaporated to dryness under a stream of nitrogen. The residue was dissolved in 0.5 ml ethanol and an aliquot served as controls. [ 25] .
The ratio plasma ubiquinone/LDL cholesterol was and Group 3 or between Group 2 and the control calculated to evaluate the independant effects of statins on cholesterol and ubiquinone metabolism. analysis of variance (ANOVA), followed by Newman-
Keuls' procedure for post hoc comparisons if the ANOVA showed a significant difference (P<0.05)
In all subjects, two evaluations of lactate and pyruvate were performed. High L/P: patients with one or two abnormal among groups. The proportions of patients with high lactate/pyruvate ratios in the different groups were evaluations (≥20 ); normal L/P: patients with two normal evaluations.
compared using Fisher's exact test. Determination of group. There was no significant difference for lactate/ not find such abnormalities in a model of simvastatininduced myopathy [ 30] . pyruvate ratios among those receiving a statin, according to the administered compound (i.e. simvastatin, pravaFibrate therapy was associated with high lactate/ pyruvate ratios in some cases. Reports on muscular statin, or fluvastatin).
syndromes related to fibrate therapy have mentioned mitochondrial abnormalities in muscle [11, 31 ] . The hypothesis of a mitochondrial dysfunction induced by Ubiquinone determinations fibrate therapy still needs to be substantiated. Elevated lactate/pyruvate ratios were also occasionally found in Results are presented Table 1 . Ubiquinone serum concentrations were lower in Group 1 (patients treated by untreated hypercholesterolaemic patients, supporting the hypothesis that hypercholesterolaemia is itself associstatins) than in Group 3 (untreated hypercholesterolaemic patients) (P<0.05). The difference was not signifiated with muscle damage [6] . The cause of mitochondrial dysfunction associated cant when the molar ratios ubiquinone/LDL cholesterol were compared. The molar ratios ubiquinone/LDL with statin therapy is unclear. The role of ubiquinone may be suspected, since treatment by statins, but not by cholesterol were significantly lower in Group 1 than in normocholesterolaemic controls (P<0.01 ). Ubiquinone fibrates was associated with low ubiquinone concentrations. Whether statins lower serum ubiquinone indeserum level was significantly higher in Group 3 (untreated hypercholesterolaemic patients) than in normopendently of LDL cholesterol lowering has been debated [13, 15, 26 ] . In this study, we found that the molar cholesterolaemic controls (P<0.05).
No correlation was found between age and plasma ratio ubiquinone/LDL cholesterol was significantly lower in patients treated with statins than in untreated level of ubiquinone in the two groups of controls, namely the normal subjects and the untreated hyperchopatients, implying that the decrease of ubiquinone did not parallel the decrease of LDL cholesterol. The lesterolaemic patients. No correlation was found between lactate/pyruvate ratio and serum ubiquinone level or absence of correlation between blood lactate/pyruvate ratio and ubiquinone serum level at the individual level between lactate/pyruvate ratio and the molar ratio ubiquinone/LDL cholesterol.
is puzzling. The relationship between serum ubiquinone and mitochondrial function is indeed unclear. The tissue biosynthesis of ubiquinone might not be reflected by its serum level [32 ] and discrepancy between very low muscular and normal circulating levels of ubiquinone Discussion has been observed in patients with mitochondrial cytopathies [33 ] . Cell culture studies failed to demonIn the present study, asymptomatic patients treated with statins, unlike those receiving fibrates, frequently had strate any mitochondrial dysfunction in cells severely depleted in ubiquinone [34 ] . Moreover, most studies an increased blood lactate/pyruvate ratio and had lower ubiquinone serum levels than untreated patients. No evaluating the effect of oral supplementation by ubiquinone in patients with mitochondrial cytopathies have correlation could be established between blood lactate/ pyruvate ratio and ubiquinone serum concentration at yielded negative results [35 ] . It is still unknown whether supplementation with oral doses of ubiquinone in statin the individual level. We also found higher serum ubiquinone levels in patients with untreated hypercholesreceivers having low serum levels of ubiquinone at the onset of therapy could prevent the occurrence of muscle terolaemia than in normocholesterolaemic subjects but there was no change in the ubiquinone/ LDL cholesterol disorders. Mitochondrial dysfunction could also be explained ratio. This result is in accordance with previous studies [26 ] .
by membrane damage induced by the inhibition of cholesterol and dolichol synthesis [ 13] . In an animal Since redox status assessed by blood lactate/pyruvate ratio may vary in a given individual and can be normal model of experimental lovastatin myopathy, the earliest changes involved the mitochondria and the sarcoplasmic one day and abnormal another day in patients with proven mitochondrial dysfunction [20, 27], we repeated reticulum [29 ] . In this hypothesis, mitochondrial dysfunction could be only one feature of a toxicity primarily evaluation of lactate and pyruvate in all subjects. The finding of high blood lactate/pyruvate ratios in 16 of 40 affecting membranous organelles [29] . We conclude that statin therapy can be associated patients receiving statins (40%) strongly supports the hypothesis of a mitochondrial dysfunction associated with high blood lactate/pyruvate ratios suggestive of mitochondrial dysfunction. Low serum levels of ubiquiwith statin therapy. In a previous study, we found high lactate/pyruvate ratios in all evaluated patients with none were also observed, but it is uncertain to what extent this feature could explain the mitochondrial zidovudine-induced mitochondrial myopathy [20] . The absence of muscular symptoms in the patients studied dysfunction. We believe that mitochondrial function could be usefully assessed in patients with muscular here may explain the lower percentage with high lactate/ pyruvate ratios. The hypothesis of a mitochondrial complications of statin therapy. dysfunction at the origin of muscular disorders due to statins had been previously suggested [9, 10, 28] . In an mitochondria [ 29] . However, other investigators did
